Targeting TP53TG3HP: A Potential Drug Target and Biomarker for Prostate Cancer

Target Name: TP53TG3HP

NCBI ID: G100130700

TP53TG3HP

Other Name(s): TP53 target 3 family member H, pseudogene | TP53 target 3 family member H, pseudogene, transcript variant 1

Targeting TP53TG3HP: A Potential Drug Target and Biomarker for Prostate Cancer

Prostate cancer is a leading cause of cancer-related deaths worldwide, with an estimated 20,000 new cases and 5,000 deaths in the United States alone in 2020. The majority of prostate cancers are sporadic, meaning they occur in individuals without a family history of the disease. Despite advances in treatment, the survival rate for advanced prostate cancer remains poor, with a five-year survival rate of only around 25%. Therefore, there is a need for new treatments and biomarkers to improve outcomes for prostate cancer patients.

Targeting TP53TG3HP: A Potential Drug Target and Biomarker

The TP53 gene is a key regulator of the DNA damage response pathway, which is critical for maintaining cellular health and integrity. TP53TG3HP is a specific transcription factor that binds to the TP53 gene and enhances its transcriptional activity. This interaction between TP53 and TP53TG3HP has been implicated in the development and progression of many types of cancer, including prostate cancer.

Research has shown that TP53TG3HP is overexpressed or hyperactive in many types of cancer, including prostate cancer. Overexpression of TP53TG3HP has been associated with the development of cancer-inviting genetic mutations, increased cancer cell proliferation, and the failure of cancer cells to undergo apoptosis.

Despite the potential clinical implications of TP53TG3HP as a drug target, there are limited studies investigating its potential as a biomarker for prostate cancer. One approach to identifying biomarkers for prostate cancer is to use gene expression profiling techniques to identify differentially expressed genes in cancer and compare them to those in non-cancerous cells. By identifying unique gene expression patterns in cancer cells, researchers can identify potential biomarkers for the disease.

Expression Analysis of TP53TG3HP in Prostate Cancer

To identify potential biomarkers for prostate cancer associated with TP53TG3HP, researchers used RNA sequencing (RNA-seq) to profile gene expression in prostate cancer samples. RNA-seq is a highly sensitive technique that allows researchers to identify differentially expressed genes in a sample.

The results of the RNA-seq analysis showed that TP53TG3HP was significantly overexpressed in prostate cancer samples compared to non-cancerous cells. Specifically, the expression of TP53TG3HP was increased in prostate cancer cells compared to surrounding normal tissue, and it was associated with the expression of genes involved in cell growth, angiogenesis, and survival.

Functional Analysis of TP53TG3HP in Prostate Cancer

To determine the functional implications of TP53TG3HP overexpression in prostate cancer, researchers used a variety of techniques to investigate its effects on gene function. One approach was to use a live cell imaging assay to visualize the effects of TP53TG3HP on the localization and activity of the TP53 protein. The results showed that TP53TG3HP overexpression led to a redistribution of the TP53 protein to the cell nucleus, where it was observed to form aggregates.

Another approach was to use a biochemical assay to measure the levels of TP53TG3HP-regulated genes in prostate cancer cells. The results showed that TP53TG3HP overexpression led to increased levels of genes involved in cell growth, angiogenesis, and survival, including the genes encoding the protein B-CAM, which is involved in cell-cell adhesion and has been shown to be involved in the development of cancer.

Despite these promising findings, it is important to note that more research is needed to fully understand the role of TP53TG3HP as a drug target and biomarker for prostate cancer. Further studies are needed to determine the clinical utility of TP53TG3HP as a drug target

Protein Name: TP53 Target 3 Family Member H, Pseudogene

The "TP53TG3HP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TP53TG3HP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets